Decoding Brain Health: Genomics of Neurological and Psychiatric Disorders in Africa

Our research is dedicated to studying the genetic basis of neurological and psychiatric disorders in African populations. This is a profoundly underserved area of global health, despite the significant burden these conditions place on individuals and communities across Africa. Neurological disorders like epilepsy, stroke, and dementias, along with psychiatric conditions such as schizophrenia, bipolar disorder, and depression, are often underdiagnosed and undertreated due to a lack of resources and, crucially, a limited understanding of their underlying biological mechanisms in African contexts.

​

Africa’s unparalleled genetic diversity means that genetic risk factors identified in predominantly European or Asian populations may not be relevant, or even present, in African individuals. This necessitates dedicated research to identify unique genetic predispositions, protective factors, and gene-environment interactions that contribute to brain disorders within African communities. By conducting comprehensive genomic studies, we aim to uncover novel genetic variants that increase susceptibility to these complex conditions, providing critical insights into their etiology and progression.

​

A core component of our work involves developing genomic tools for the early diagnosis and treatment of neurodevelopmental and neurodegenerative disorders. Early and accurate diagnosis is vital for these conditions, as it allows for timely intervention, potentially slowing progression, managing symptoms more effectively, and improving quality of life. For neurodevelopmental disorders like autism spectrum disorder or intellectual disabilities, genomic tools can help identify the genetic causes, paving the way for personalized educational and therapeutic support. Similarly, for neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, identifying genetic markers can enable earlier detection, facilitating participation in clinical trials for new treatments and allowing for proactive management strategies. Our efforts in Nairobi and across the continent are geared towards translating these genomic discoveries into practical diagnostic assays and informing the development of targeted therapies that are truly effective for African patients.